Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: General Population Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00731120
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Phase 3 Interventional

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00658372
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Arcadia, California • Costa Mesa, California • Escondido, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 27, 2026, 1:24 PM EDT
Completed No phase listed Observational

Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population

NCT02229032
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 50 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Generalized Anxiety Disorder Adjunct Study

NCT00534599
View directory record Official record
Conditions
Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
Interventions
Placebo, quetiapine fumarate XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 27, 2026, 1:24 PM EDT
Completed No phase listed Observational

Use of Virtual Reality to Communicate Concepts of Genomics to the General Public

NCT00316056
View directory record Official record
Conditions
Healthy, Learning, Communication
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 40 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study

NCT00689091
View directory record Official record
Conditions
Awareness During General Anesthesia
Interventions
Bispectral Index Monitor, Electronic MAC alert
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
22,185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD

NCT03676725
View directory record Official record
Conditions
ADHD, PMS
Interventions
Lidocaine gel
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Mental Acuity in Elderly Populations Through Incentive for Technology Use

NCT00805259
View directory record Official record
Conditions
Cognitive Function
Interventions
Financial incentives
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
55 Years to 85 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

NCT04940624
View directory record Official record
Conditions
Dravet Syndrome (DS)
Interventions
Soticlestat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 21 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Impact of Exercise on Diastasis Rectus Abdominus

NCT04049487
View directory record Official record
Conditions
Diastasis Recti and Weakness of the Linea Alba
Interventions
Exercise
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 27, 2026, 1:24 PM EDT
Active, not recruiting Phase 4 Interventional

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819
View directory record Official record
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions
Cannabidiol
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Available No phase listed Expanded access

Intermediate-Size Expanded Access Protocol (EAP) for LP352

NCT06149663
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
Interventions
LP352
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
U.S. locations
19
States / cities
Downey, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

NCT00002048
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00734071
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Anaheim, California • Arcadia, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

NCT01882647
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
000-0551 Lotion, Vehicle Lotion
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Brandon, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

NCT04399837
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Auburn Hills, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

NCT01871402
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
000-0551 Lotion, Vehicle Lotion
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Arlington Heights, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional

Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population

NCT04895995
View directory record Official record
Conditions
Anxiety Disorders, Cardiovascular Diseases, Anxiety, Health Behavior
Interventions
Daylight dCBT Application
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

NCT02926898
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sleep and Breathing in the General Population - Chemical Stimuli

NCT04720547
View directory record Official record
Conditions
Sleep-disordered Breathing
Interventions
Zolpidem, No Treatment
Drug · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

NCT00808249
View directory record Official record
Conditions
Anxiety Disorders
Interventions
AZD7325, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
52
States / cities
Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 27, 2026, 1:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Racial Disparities in the Expression of Paranoia

NCT07460453
View directory record Official record
Conditions
Paranoia, Psychotic Disorders
Interventions
Guided Visual Imagery Task
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 27, 2026, 1:24 PM EDT